BiotechTube

Fludarabine + Cyclophosphamide + PRGN-3007

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Lymphocytic Leukemia

Conditions

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Triple Negative Breast Cancer Malignancies

Trial Timeline

Jan 25, 2023 → Apr 18, 2024

NCT ID
NCT05694364

About Fludarabine + Cyclophosphamide + PRGN-3007

Fludarabine + Cyclophosphamide + PRGN-3007 is a phase 1 stage product being developed by Precigen for Chronic Lymphocytic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05694364. Target conditions include Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05694364Phase 1Completed

Competing Products

20 competing products in Chronic Lymphocytic Leukemia

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
76
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
TERN-701Terns PharmaceuticalsPhase 1/2
38
LY3556050 + PlaceboEli LillyPhase 2
52
THB001Third Harmonic BioPhase 1
25
BriquilimabJasper TherapeuticsPhase 1/2
33
BriquilimabJasper TherapeuticsPhase 1/2
33
BriquilimabJasper TherapeuticsPhase 2
44
Empagliflozin + Matching placeboEli LillyPhase 3
77
LY3461767 + PlaceboEli LillyPhase 1
33
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
77
LY3526318 + PlaceboEli LillyPhase 2
52
PirtobrutinibEli LillyPhase 2
52
Ibrutinib + LY3214996Eli LillyPhase 1
33
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
52
LYR-210Lyra TherapeuticsPhase 2
44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)Lyra TherapeuticsPhase 2
44
480 Mometasone Furoate Sinus Drug DepotLyra TherapeuticsPhase 1
25
LYR-210 + Sham procedure controlLyra TherapeuticsPhase 3
69
LYR-210 + Sham procedure controlLyra TherapeuticsPhase 3
69

Other Products from Precigen

Zopapogene imadenovec (Zopa)Approved
80
PRGN-2009 plus Pembrolizumab + Pembrolizumab alonePhase 2
47
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2Phase 1/2
36
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePhase 1/2
36
INXN-4001Phase 1
28